Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.59 |
| ▸ | BRD4 | O60885 | 6/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL1B | P01584 | 1/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31526946 | 0.99 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL31526908 | 0.99 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL17884396 | 0.99 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL30786799 | 0.99 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL17873770 | 0.99 | CRBN (0.58) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL20933080 | 0.97 | CRBN (0.60) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26321021 | 0.95 | CRBN (0.64) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL13584375 | 0.94 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26321035 | 0.94 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B | |
| SCHEMBL26323874 | 0.94 | CRBN (0.63) | CRBNBRD4IKZF1TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | claimed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| WO-2025075947-A1 | SELECTIVE TC-PTP DEGRADERS FOR CANCER IMMUNOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-04 | — | — | US | disclosed |
| EP-4119552-A1 | REGULATING CHIMERIC ANTIGEN RECEPTORS | Dana-Farber Cancer Institute, Inc. (US) | 2023-01-18 | — | — | EP | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3440066-B1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017024319-A1 | TUNABLE ENDOGENOUS PROTEIN DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024318-A1 | TARGETED PROTEIN DEGRADATION TO ATTENUATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE INFLAMMATORY RESPONSES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2017007612-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | CRBN 45/4885BRD4 1479/4885IKZF1 471/4885 |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | CRBN 605/4885BRD4 1670/4885IKZF1 618/4885 |
| US-11691984-B2 | Compounds and methods for DCAF-mediated protein degradation | DCAF1, CUL4A, DCAF15 | CRBN 26/4885BRD4 153/4885IKZF1 334/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | CRBN 151/4885BRD4 1542/4885IKZF1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.